Radiation + Cemiplimab ± Fianlimab for Bladder Cancer

This trial explores whether combining radiation therapy with immunotherapy drugs, cemiplimab and possibly fianlimab, can effectively and safely treat muscle-invasive bladder cancer before surgery. The goal is to determine if this approach can improve treatment outcomes for those with this type of bladder cancer. Participants must have a confirmed diagnosis of muscle-invasive bladder cancer and be eligible for surgery but cannot use cisplatin-based therapy due to specific health reasons. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to potentially groundbreaking advancements in bladder cancer treatment.

The trial does not specify if you need to stop taking your current medications. However, you cannot use certain immunosuppressive drugs or systemic corticosteroids above a certain dose, and these must be stopped 14 days before starting the trial treatment. It's best to discuss your specific medications with the study team.

Research has shown that cemiplimab, already used for some skin cancers, is generally well-tolerated. In a large study, only 0.7% of patients experienced serious kidney-related side effects, with most handling the treatment without major problems.

When combined with fianlimab, early research suggests this combination is usually safe. Studies involving patients with advanced kidney cancer found the combination well-tolerated and effective over time. Most patients did not experience severe side effects, and the treatment remained effective for an extended period.

Researchers are excited about these treatments for bladder cancer because they combine advanced immunotherapy with radiation. Cemiplimab is a checkpoint inhibitor that helps the immune system recognize and attack cancer cells more effectively. When paired with stereotactic body radiotherapy (SBRT), it may enhance the body's ability to target tumors precisely and aggressively. Adding Fianlimab to the mix could further boost this immune response, offering a potentially more powerful and targeted approach than traditional treatments like chemotherapy or standard radiation alone. This combination could lead to better outcomes by bolstering the body's natural defenses against cancer.

Research has shown that cemiplimab, when combined with radiation therapy, yields promising results for treating certain cancers. In earlier studies, it reduced the risk of cancer recurrence or death by 68%. Many patients experienced tumor shrinkage or halted growth, indicating a high response rate. In this trial, one group of participants will receive radiation therapy and cemiplimab, while another group will receive radiation therapy combined with cemiplimab and fianlimab. The combination of cemiplimab and fianlimab has also produced encouraging results. More than half of the patients responded positively, with some achieving complete recovery. These findings suggest that this combination could effectively treat muscle-invasive bladder cancer.⁴⁶⁷⁸⁹